kabutan
N225

65,606.71

-0.12%

TOPIX

4,074.93

+0.47%

USDJPY

158.35

-0.08%

ZERIA PHARMA, First Half Ordinary Profit Decreases by 67%, Jul-Sep Ordinary Profit Decreases by 60%

Wed Nov 5, 2025 4:00 pm JST Earnings

4559 ZERIA PHARMACEUTICAL CO.,LTD. 【J-GAAP】

Earnings Report

ZERIA PHARMACEUTICAL CO.,LTD. <4559> [TSE Prime] announced its financial results after the market closed on November 5th (16:00). The consolidated ordinary profit for the cumulative second quarter of the fiscal year ending March 2026 (April to September) significantly dropped 66.6% from the same period last year to 2.65 billion yen. Progress toward the full-year plan of 12.0 billion yen was 22.1%, also falling below the five-year average of 57.6%.

Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit for the October to March period (second half) is expected to expand 91.0% from the same period last year, reaching 9.34 billion yen.

In the most recent three-month period, from July to September (2Q), the consolidated ordinary profit significantly dropped to 0.99 billion yen, a 60.1% decrease compared to the same period last year. The operating profit margin decreased from 12.0% in the same period last year to 10.4%.

Kabutan News

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating
Profit
Ordinary
Profit
Net
Profit
Adj.
EPS
Progress Rate
vs. First Half
Announce Accounting
Standards
Apr - Sep, 2023
36,678M 5,327M 5,495M 5,396M 122.4 64.5 Nov 1, 2023 J-GAAP
Apr - Sep, 2024
42,422M 6,459M 7,949M 6,061M 137.5 61.9 Nov 6, 2024 J-GAAP
Apr - Sep, 2025
39,960M 3,641M 2,656M 1,737M 39.4 22.1 Nov 5, 2025 J-GAAP
YoY -5.8% -43.6% -66.6% -71.3% -71.3%
First Half Results vs. Previous Guidance
Fiscal Year Revenue Operating
Profit
Ordinary
Profit
Net
Profit
Adj.
EPS
Adj.
Dividend
Announce Accounting
Standards
Apr - Sep, 2025 Guidance 39,960M 3,640M 2,650M 1,730M 39.3 24 Oct 31, 2025 J-GAAP
Apr - Sep, 2025 Results 39,960M 3,641M 2,656M 1,737M 39.4 24 Nov 5, 2025 J-GAAP
Revision Rate 0.0% +0.0% +0.2% +0.4% +0.4%

Current Period Guidance

Second Half Results
Fiscal Year Revenue Operating
Profit
Ordinary
Profit
Net
Profit
Adj.
EPS
Adj.
Dividend
Announce Accounting
Standards
Oct - Mar, 2024
44,889M 5,738M 4,891M 3,875M 87.9 24 May 8, 2025 J-GAAP
Guidance
Oct - Mar, 2025
50,040M 8,359M 9,344M 7,763M 176.1 24 Nov 5, 2025 J-GAAP
YoY +11.5% +45.7% +91.0% +100.3% +100.3%
Current Period Guidance
Fiscal Year Revenue Operating
Profit
Ordinary
Profit
Net
Profit
Adj.
EPS
Adj.
Dividend
Announce Accounting
Standards
Mar, 2024
75,725M 9,621M 8,513M 7,731M 175.4 44 May 9, 2024 J-GAAP
Mar, 2025
87,311M 12,197M 12,840M 9,936M 225.4 47 May 8, 2025 J-GAAP
Guidance
Mar, 2026
90,000M 12,000M 12,000M 9,500M 215.5 48 May 8, 2025 J-GAAP
YoY +3.1% -1.6% -6.5% -4.4% -4.4%

Quarterly Results

Fiscal Year Revenue Operating
Profit
Ordinary
Profit
Net
Profit
Adj.
EPS
Operating
Profit Margin
Announce Accounting
Standards
Jul - Sep, 2024
20,967M 2,520M 2,490M 1,849M 42.0 12.0 Nov 6, 2024 J-GAAP
Oct - Dec, 2024
22,351M 3,787M 2,712M 2,165M 49.1 16.9 Feb 5, 2025 J-GAAP
Jan - Mar, 2025
22,538M 1,951M 2,179M 1,710M 38.8 8.7 May 8, 2025 J-GAAP
Apr - Jun, 2025
19,489M 1,520M 1,662M 1,090M 24.8 7.8 Aug 5, 2025 J-GAAP
Jul - Sep, 2025
20,471M 2,121M 994M 647M 14.7 10.4 Nov 5, 2025 J-GAAP
YoY -2.4% -15.8% -60.1% -65.0% -65.0%